-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Apellis Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q4 2024.
- Apellis Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending December 31, 2024 was -$26.2M, a 69% increase year-over-year.
- Apellis Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending December 31, 2024 was -$165M, a 68.1% increase year-over-year.
- Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2024 was -$165M, a 68.1% increase from 2023.
- Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$517M, a 13% increase from 2022.
- Apellis Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$595M, a 10.9% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)